Comparison · NCT01067144-sae
Gabapentin vs Control: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Gabapentin vs Control: serious adverse events. Trial comparisons, record NCT01067144-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01067144-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00962 | 0.00264 | 0.0344 | wilson | |
| Risk in group 2 | 0.0099 | 0.00272 | 0.0354 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000286 | -0.0267 | 0.0255 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.971 | 0.138 | 6.83 | log | |
| Odds ratio, group 1 over group 2 | 0.971 | 0.135 | 6.96 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Gabapentin than on Control | 3,500 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Gabapentin | 1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period. | 2 | 208 | EG001 |
| Group 2 | Control | Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively. | 2 | 202 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 2 years
Source ClinicalTrials.gov
Trial
- Title
- Stanford Accelerated Recovery Trial (START)
- NCT number
- NCT01067144
- Phases
- PHASE3
- Conditions
- Pain, Breast Cancer, Lung Cancer
- Interventions
- Gabapentin, Lorazepam (active control), Placebo (inactive)
- Lead sponsor
- Stanford University
- Results first posted
- 2018-06-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01067144?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01067144-sae